Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Product Spotlight

Nova Biomedical

Stat Profile Prime Plus

Company

Nova Biomedical

Name of instrument

Stat Profile Prime Plus

Email

info@novabio.com

City, State

Waltham, MA

Phone

800-458-5813  

Website

https://www.novabiomedical.com

Type of instrument

chemistry

Operational type/Model type

random access/benchtop

List price/First year sold in U.S.

—/2018

Targeted hospital bed size/Targeted test volume

—

Company manufactures instrument

yes (also sold by distribution partners)

Other models in this family of analyzers

Stat Profile Prime CCS, Stat Profile Prime, Stat Profile Prime ES

No. of units in clinical use in U.S./Outside U.S. (countries)

—

Dimensions (H × W × D)/Instrument footprint

18 × 14 × 16 in./1.5 sq. ft. 

Weight empty/Weight fully loaded

35 lbs./42 lbs.

No. of different measured assays onboard simultaneously

20 (20 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

30 (30 can be active simultaneously)

Test throughput per hour/Assay run time

up to 38 (760 tests in throughput)/avg. 90 sec.

No. of direct ion-selective electrode channels

7

Detection methods

photometry, potentiometry, Severinghaus, amperometry, conductivity, enzyme

Stat time until completion/specimen throughput for ion-selective electrode

90 sec./38 specimens per hr.

Stat time until completion/specimen throughput for basic metabolic panel

90 sec./38 specimens per hr.

Stat time until completion/specimen throughput for complete metabolic panel

90 sec./38 specimens per hr.

Typical time delay from ordering stat test until aspiration of sample

3 sec.

Fully automated microplate immunoassay system

—

Methodologies supported

—

Separation methodologies

—

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

—

• Typical time delay from test order to aspiration of sample

—

Approximate No. of tests per reagent set/Reagent type

100, 200, 300, 400, or 500/self-contained multiuse

Reagents refrigerated onboard/Reagents ready to use

no/yes

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

liquid chemistry (closed reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/1 min. or 1 specimen or 20 tests/assays

Design of sample-handling system

probe

Uses washable cuvettes/Uses disposable cuvettes

no/yes

Min.–max. sample volume that can be aspirated at one time 

90–135 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

135 µL/135 µL/—

Dedicated pediatric sample cup

no

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/yes

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

detection for hemolysis, clots

Dilutes patient samples onboard/Susceptibility to carryover

no/—

Automatic rerun capability

no

Sample volume can be diluted to rerun out-of-linear-range high results

no

Sample volume can be concentrated to rerun out-of-linear-range low results

no

Autocalibration/Multipoint calibration supported

yes (calibrants can be stored onboard)/yes

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—

Automatic programmable start/Automatic programmable shutdown

yes (5 min. avg. start-up time)/yes

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

automated collection onboard instrument

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128)/yes

Lab can control analyzer from remote computer

yes

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

yes (optional)

Data-management capability/LIS or EHR systems interfaced

onboard, optional add-on (NovaNet, more)/—

LIS interface provided/Bidirectional interface capability

yes (included in instrument price)/yes (broadcast download and host query)

Modem servicing provided/Service engineer on-site response time

no/within 8 hrs.

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

—

Maintenance records kept onboard for user/vendor

yes/yes (both include audit trail of who replaced parts)

Maintenance training demonstration module onboard

yes

Training included with purchase/Avg. time for basic user training

yes/30 min. (at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

yes/no

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (5 years)/—

Distinguishing features (supplied by company)

maintenance-free MicroSensor Card and disposable cartridge technology for sensors and reagents; broad menu including iMg, BUN, creatinine/eGFR CO-oximetry, estimated plasma volume; automated, liquid QC and supplemental quality monitoring for EP23-A compliance and real-time verification of all analytical components during calibration, sample analysis, QC analysis

Note

all information listed was provided to CAP TODAY in 2025; company did not provide updated information by 2026 entry deadline

More products
in this guide

DxC 500 AU Clinical Chemistry Analyzer
DxC 500i Clinical Analyzer
Pictus 500 (P500)
DS2 Elite Automated ELISA System
VITROS XT 3400 Chemistry Systems
cobas pure integrated solutions 
B⋅R⋅A⋅H⋅M⋅S KRYPTOR compact PLUS